If you’ve been researching alternatives to traditional testosterone replacement therapy (TRT), you may have come across a medication called enclomiphene. It’s generating significant interest in the men’s health community — and for good reason. Enclomiphene offers the potential to raise testosterone levels while preserving fertility, with fewer side effects than its parent compound, clomiphene citrate (Clomid).
But enclomiphene’s regulatory status, clinical evidence, and availability are more complicated than the online hype might suggest. In this article, we’ll give you an honest, evidence-based breakdown of what enclomiphene is, how it works, what the research shows, and where it stands in UK clinical practice.
What Is Enclomiphene?
Enclomiphene is the purified trans-isomer of clomiphene citrate. To understand what that means, we need to briefly revisit the chemistry of Clomid.
Clomiphene citrate — the drug that has been used off-label for decades to treat low testosterone in men — is actually a mixture of two chemical isomers:
- Enclomiphene (trans-clomiphene): Makes up approximately 62% of the clomiphene mixture. It is the isomer responsible for the desired anti-oestrogenic effects at the hypothalamus and pituitary gland — the mechanism that stimulates testosterone production.
- Zuclomiphene (cis-clomiphene): Makes up approximately 38% of the mixture. It has a much longer half-life (weeks versus hours) and possesses weak oestrogenic properties. This means it can actually activate oestrogen receptors rather than block them, potentially counteracting some of enclomiphene’s benefits and contributing to side effects.
Enclomiphene, as a standalone drug, removes the zuclomiphene isomer entirely. The idea is simple: keep the part that works and eliminate the part that may cause problems.
How Does Enclomiphene Work?
Enclomiphene works through the same fundamental mechanism as clomiphene citrate, but without the confounding effects of zuclomiphene.
The Mechanism
Enclomiphene is a selective oestrogen receptor modulator (SERM). It blocks oestrogen receptors at the hypothalamus and pituitary gland, preventing oestradiol from exerting its normal negative feedback. The brain interprets this as a low-oestrogen state and responds by increasing production of:
- Gonadotropin-releasing hormone (GnRH) from the hypothalamus
- Luteinising hormone (LH) from the pituitary — which stimulates the testes to produce more testosterone
- Follicle-stimulating hormone (FSH) from the pituitary — which supports sperm production
The result is an increase in endogenous (the body’s own) testosterone production, with preservation of both testicular function and spermatogenesis. This is a critical distinction from TRT, which replaces testosterone from an external source and typically shuts down the body’s own production.
Why Removing Zuclomiphene Matters
Zuclomiphene’s long half-life means it accumulates in the body over time. Because it has weak oestrogenic activity, this accumulation can:
- Partially counteract the anti-oestrogenic effects of enclomiphene
- Contribute to elevated oestradiol levels
- Cause side effects such as visual disturbances, mood changes, and gynaecomastia
- Reduce the overall efficacy of treatment
By isolating enclomiphene, the goal is to achieve a cleaner pharmacological profile: more effective testosterone stimulation with fewer oestrogenic side effects.
What Does the Clinical Evidence Show?
Enclomiphene has been studied in several clinical trials, primarily under the development name Androxal by the pharmaceutical company Repros Therapeutics (later acquired by Allergan).
Key Clinical Findings
- Effective testosterone elevation: Phase II and Phase III trials demonstrated that enclomiphene 12.5mg and 25mg daily significantly raised total testosterone levels in men with secondary hypogonadism, often into the normal range (above 300 ng/dL or approximately 10.4 nmol/L).
- Preservation of sperm production: Unlike TRT, which consistently reduces sperm count, enclomiphene maintained or improved sperm parameters in clinical trials. This is a major advantage for men of reproductive age.
- Improved LH and FSH: Enclomiphene consistently raised gonadotropin levels, confirming its mechanism of stimulating the HPG axis rather than suppressing it.
- Symptom improvement: Several trials reported improvements in energy, mood, and sexual function, though the degree of symptom relief varied between studies and between individuals.
Head-to-Head With Testosterone
Some trials directly compared enclomiphene to topical testosterone (AndroGel). Key observations:
- Both treatments raised testosterone levels effectively
- Testosterone gel produced more consistent testosterone elevation in some patients
- Enclomiphene preserved LH, FSH, and sperm production, while testosterone gel suppressed all three
- Men on enclomiphene maintained testicular volume; men on testosterone gel experienced reduction
Head-to-Head With Clomiphene
Fewer studies have directly compared enclomiphene to the mixed clomiphene citrate. However, the theoretical advantages are supported by pharmacological data showing:
- A cleaner anti-oestrogenic profile without the oestrogenic contribution of zuclomiphene
- A shorter half-life, allowing more predictable dosing and fewer accumulation-related effects
- Potentially fewer visual disturbances and mood-related side effects, though large comparative trials are needed to confirm this
Enclomiphene vs Clomiphene vs TRT: A Comparison
| Factor | Enclomiphene | Clomiphene (Clomid) | TRT (Testosterone) |
|---|---|---|---|
| Mechanism | Stimulates natural T production (SERM) | Stimulates natural T production (SERM) | Replaces testosterone externally |
| Effect on fertility | Preserves/improves sperm | Preserves/improves sperm | Suppresses sperm production |
| Oestrogenic effects | Minimal (pure anti-oestrogen) | Mixed (zuclomiphene has oestrogenic activity) | Indirect (via aromatisation) |
| Visual side effects | Less likely | Possible | Not typical |
| Symptom relief | Moderate (varies) | Moderate (varies) | Generally more robust |
| Testicular size | Maintained | Maintained | Typically decreases |
| MHRA approval (UK) | Not approved | Approved for female infertility (off-label in men) | Approved for male hypogonadism |
| Availability in UK | Limited (not routinely available) | Available on prescription | Available on prescription |
Current Regulatory Status
In the UK
Enclomiphene is not currently approved by the MHRA (Medicines and Healthcare products Regulatory Agency) for any indication. This means it cannot be legally prescribed as a licensed medication in the UK.
The drug’s regulatory journey has been complicated. Repros Therapeutics submitted a New Drug Application (NDA) to the US FDA, which issued a Complete Response Letter requesting additional data. The drug has not yet received FDA approval either, and the development programme has faced various setbacks.
Some compounding pharmacies in other countries (notably the US) produce enclomiphene, and it is available through certain international sources. However, importing unlicensed medications carries legal and safety considerations, and we would always recommend using treatments that are available through regulated channels with proper clinical oversight.
In Other Countries
The availability of enclomiphene varies internationally:
- United States: Not FDA-approved, but available through some compounding pharmacies and men’s health clinics
- Australia: Available through some compounding pharmacies
- Europe: Generally not approved or widely available
- India: Some generic formulations available
Who Might Benefit From Enclomiphene?
If and when enclomiphene becomes available in the UK through regulated channels, the men most likely to benefit would include:
- Men with secondary hypogonadism: Those whose low testosterone is caused by inadequate signalling from the brain (hypothalamus/pituitary) rather than testicular failure. Enclomiphene works by amplifying these signals, so the testes need to be capable of responding.
- Men wanting to preserve fertility: Like clomiphene, enclomiphene maintains or improves sperm production — critical for men who want to have children.
- Men who experienced side effects on clomiphene: The removal of the zuclomiphene isomer may mean better tolerability, particularly for visual disturbances and mood-related side effects.
- Younger men: Who may want a reversible treatment option before considering long-term TRT.
- Men on TRT who want to transition off: Enclomiphene could potentially be used to help restart natural testosterone production after a period of exogenous testosterone use, similar to how clomiphene is sometimes used in post-cycle recovery.
Why Is Enclomiphene Generating So Much Interest?
The enthusiasm around enclomiphene — particularly in online health communities and men’s health forums — reflects several converging trends:
1. Growing Demand for Fertility-Preserving Options
As men become better informed about the fertility-suppressing effects of TRT, demand for alternatives that raise testosterone without compromising reproductive function is increasing. Enclomiphene fits this need.
2. Dissatisfaction With Clomiphene’s Side Effects
While clomiphene is effective for many men, a significant minority experience troublesome side effects that appear to be related to the zuclomiphene isomer. The promise of a “cleaner” version is appealing.
3. Desire for Oral Treatment
Many men prefer taking a tablet to administering injections or applying gels. Enclomiphene offers the convenience of oral dosing with a mechanism that supports, rather than replaces, natural hormone production.
4. Shifting Attitudes to Men’s Health
There is a broader cultural shift towards men taking proactive ownership of their hormonal health. This has created a market for innovative treatments that go beyond the traditional TRT model. For more on this topic, read our article on why men delay seeking help for low testosterone.
Potential Concerns and Limitations
Despite the enthusiasm, there are important caveats to consider:
- Limited long-term data: While the clinical trials are promising, we don’t have the decades of real-world experience that we have with testosterone or even clomiphene. Long-term safety data is incomplete.
- Regulatory uncertainty: Without MHRA or FDA approval, quality control and standardisation of available formulations (particularly from compounding pharmacies) is variable.
- Not a guaranteed improvement over clomiphene: The theoretical advantages of removing zuclomiphene are logical, but large-scale head-to-head trials proving superior clinical outcomes are lacking.
- May not match TRT for symptom relief: Like clomiphene, enclomiphene raises testosterone through endogenous production, which may not achieve the same consistent levels or symptom relief as direct testosterone replacement in all patients.
- Still requires functioning testes: Men with primary hypogonadism (testicular failure) will not respond to enclomiphene, just as they do not respond to clomiphene.
The Future of Enclomiphene in UK Practice
The trajectory of enclomiphene in the UK will depend on several factors:
- Regulatory approval: If a pharmaceutical company brings enclomiphene through the MHRA approval process, it could become a mainstream treatment option. However, this requires significant investment and there is currently no clear timeline.
- Compounding pharmacy availability: As the UK compounding sector evolves, there may be increased access through this route, though this raises questions about quality assurance and prescriber responsibility.
- Clinical guideline inclusion: If bodies like the BSSM or specialist endocrine societies include enclomiphene in their guidelines, it would encourage wider prescribing.
- Competitive landscape: The development of other SERMs or alternative approaches to preserving fertility alongside testosterone optimisation could influence enclomiphene’s niche.
At Evernu, we stay at the forefront of developments in men’s hormonal health. As the evidence base and regulatory landscape for enclomiphene evolve, we will incorporate it into our treatment options where appropriate and safe to do so.
What Are Your Options Right Now?
While enclomiphene’s future looks promising, you don’t need to wait for it to address your symptoms today. If you’re experiencing signs of low testosterone, there are well-established, evidence-based treatments available right now:
- Testosterone replacement therapy: The gold standard for symptom relief, available in various forms (injections, gels, patches). Learn more about our TRT options.
- Clomiphene citrate: An effective oral option for men who want to preserve fertility, available off-label through specialist clinics. Read our detailed guide on Clomid for low testosterone.
- Lifestyle optimisation: Weight management, exercise, sleep improvement, and stress reduction can all support testosterone levels alongside medical treatment.
Taking the First Step
Whether you’re interested in enclomiphene, clomiphene, TRT, or simply want to understand what’s going on with your hormones, the first step is the same: get a clear picture of your current levels and symptoms.
Our free symptom assessment takes less than two minutes and gives you an immediate indication of whether low testosterone could be contributing to how you’re feeling. From there, our at-home blood test provides a comprehensive hormone panel that our clinicians use to build a personalised treatment plan.
The world of men’s hormonal health is evolving rapidly, and treatments like enclomiphene represent exciting developments. But the most important step isn’t choosing the perfect treatment — it’s starting the conversation about your health.
Key Takeaways
- Enclomiphene is the purified trans-isomer of clomiphene citrate, designed to stimulate natural testosterone production without the oestrogenic effects of zuclomiphene.
- Clinical trials show it effectively raises testosterone while preserving fertility and testicular function.
- It is not currently MHRA-approved in the UK and is not routinely available through regulated channels.
- The theoretical advantages over clomiphene include fewer side effects and a cleaner pharmacological profile, but large comparative trials are limited.
- It is best suited for men with secondary hypogonadism who want to preserve fertility.
- Effective, evidence-based treatments for low testosterone (TRT and clomiphene) are available now and should not be delayed while waiting for newer options.
- Always seek treatment through regulated medical channels with proper clinical oversight.
This article is for informational purposes only and does not constitute medical advice. The regulatory and availability status of enclomiphene may change over time. Always consult a qualified healthcare professional before starting any medication. Explore our current testosterone treatment options or take our free symptom assessment.
